These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7923250)

  • 21. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
    Belli F; Arienti F; Rivoltini L; Santinami M; Mascheroni L; Prada A; Ammatuna M; Marchesi E; Parmiani G; Cascinelli N
    Melanoma Res; 1992 Nov; 2(4):263-71. PubMed ID: 1490114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y; Tanaka T; Tanji Y; Fujiwara A; Taguchi T
    Biotherapy; 1994; 8(1):41-50. PubMed ID: 7547080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study.
    Ferlazzo G; Scisca C; Iemmo R; Cavaliere R; Quartarone G; Adamo V; Frazzetto G; Costa G; Melioli G
    J Immunother; 1997 Mar; 20(2):158-63. PubMed ID: 9087388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cellular immunotherapy of primary brain tumors.
    Hayes RL
    Rev Neurol (Paris); 1992; 148(6-7):454-66. PubMed ID: 1448666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
    Blacklock JB; Grimm EA
    Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
    [No Abstract]   [Full Text] [Related]  

  • 35. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K
    Nihon Ika Daigaku Zasshi; 1992 Oct; 59(5):418-27. PubMed ID: 1430114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
    Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
    J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
    Yeung AW; Pang YK; Tsang YC; Wong SW; Leung JS
    Cancer; 1993 Jun; 71(11):3633-9. PubMed ID: 8387882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.
    Mie K; Shimada T; Akiyoshi H; Hayashi A; Ohashi F
    Vet Immunol Immunopathol; 2016 Sep; 177():58-63. PubMed ID: 27436446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.